NCT04710498View on ClinicalTrials.gov

Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma

PHASE2CompletedINTERVENTIONAL

Enrollment

20

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

February 7, 2024

Study Completion Date

February 15, 2024

Conditions

Cutaneous Squamous Cell Carcinoma

Interventions

DRUG

Atezolizumab

Atezolizumab administered intravenous (IV) infusion at a fixed dose of 1200 mg

Trial Locations (1)

94304

Stanford University, Stanford

Sponsors

Collaborators (1)

Genentech, Inc.

All Listed Sponsors

collaborator

Genentech, Inc.

INDUSTRY

lead

Stanford University

OTHER

NCT04710498 - Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | Biotech Hunter | Biotech Hunter